NCT06507930
The COMPASSION Study
StatusRecruiting
PhaseNot applicable
SponsorDana-Farber Cancer Institute
Primary completion (estimated)
At risk: Primary completion moved 2 years later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Oct 1, 2026 to Oct 1, 2028
- Eligibility criteria expanded, about 11 words
- Study completion pushed from Mar 1, 2027 to Mar 1, 2029
- Notable Primary completion date: Sep 1, 2025 to Oct 1, 2026
- Study completion date: Mar 1, 2026 to Mar 1, 2027
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jan 2025 to Sep 1, 2024
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Proportion of Participant Intervention Completion
Timeframe: Up to 4 weeks
Arms and interventions
Usual Care CohortNo intervention
25 participants will complete study procedures as follows: * Introduction to study and survey by brief, verbal consent via phone call. * At 4-6 weeks: survey completion via email or phone.
Compassion CohortExperimental
25 participants will complete study procedures as follows: * Introduction to study and survey by brief, verbal consent via phone call. * At 4-6 weeks: survey completion via email or phone. * 4 weekly check-ins via Zoom or phone call with study team.
Other: Telehealth Hospice Visits
Sites
1 site in 1 country
- Dana-Farber Cancer InstituteBoston, Massachusetts, United States